Gene Logic Says Genomics Revenue 'Significantly Lower' Than Expected for Q2 and 2005
Gene Logic said last week that revenue for its genomics division will be "significantly lower" than anticipated for both the second quarter and the full year of 2006, and it is withdrawing its financial guidance for 2006 and 2007 as a result.
The disappointing revenues will adversely impact operating results for the genomics division "for the foreseeable future," the company said.
The company said it is performing a review of the genomics division's strategy, and it expects to announce those results within 90 days. The performance of Gene Logic's drug repositioning division and its preclinical division will not deviate significantly from estimates, the company said.
Dennis Rossi, the company's senior vice president and general manager of genomics, has resigned for "personal reasons and to pursue other career opportunities," the company said.
A spokesperson for Gene Logic declined to comment on the current situation at the company.
CombiMatrix Molecular Diagnostics to Launch CGH Service in US in August
CombiMatrix Molecular Diagnostics this week said it plans to launch its first molecular diagnostic service in the US in August.
The service uses CMDX's Constitutional Genetic Array Test, which it claims can genetically identify more than 50 common genetic disorders, including developmental disorders. The service is already sold in Europe through Paris-based Array Genomics.
CMDX said it's in the "final phases" of internal human and clinical validation.
In March, CMDX and Array Genomics said they plan to co-develop and co-market a series of comparative genomic hybridization microarrays for diagnosing genetic anomalies associated with mental retardation.
Matt Watson, CEO of CMDX, said in a statement that the subsidiary is "actively developing further tests based on both our oligo and BAC capabilities that augment our microarray portfolio and over the next three quarters, we have plans to launch three to five additional products into the molecular diagnostics market."
University of Edinburgh Picks Up Arrayjet Microarray Spotter
Arrayjet said last week that the University of Edinburgh has purchased one of its Aj120 inkjet microarray spotters.
The spotter has been installed in the Scottish Center for Genomic Technology and Informatics, and replaces an alpha prototype spotter SCGTI purchased from Arrayjet in 2004, the company said.
Duncan Hall, Arrayjet's director of sales and marketing, told BioArray News last week that the SCGTI deal reflects an interest the company has observed in the number of researchers interested in evaluating and purchasing its spotters for a "variety of DNA and non-DNA applications."
Financial details of the purchase were not disclosed.
DNAvision Upgrades Its Affy System to Offer Custom SNP Genotyping
DNAVision has upgraded one of its GeneChip systems with Affymetrix's new GeneChip 3000 targeted genotyping system for its custom genotyping services, the company said last week.
According to DNAVision's chief executive officer, Jean-Pol Detiffe, the new system makes the company the first full-service pharmacogenomic laboratory to provide this service in Europe.
The GeneChip scanner incorporates MIP and Universal Tag technologies to allow flexible multiplexing from 1,500 to 50,000 SNPs per individual assay, DNAVision said in a statement.
Shin Nippon Biomedical Labs, Takeda Develop Cynomolgus Monkey Array
Shin Nippon Biomedical Laboratories said this week that it has completed a joint research project with Takeda Pharmaceutical.
According to SNBL, the partners have created a customized DNA microarray that mounts representative sequences from 15,000 cynomolgus monkey genes. SNBL said that the customized DNA microarray can be used to evaluate toxicity in primates.
Also, the partners have developed a gene expression database for 27 organs used in toxicity analysis. In total, SNBL and Takeda analyzed genes expressed in the six main organs of cynomolgus monkeys and established a database that covers the entire genome sequence of the cynomolgus monkey, SNBL said.
The two Japanese companies have been analyzing organ-specific virulence-associated genes of cynomolgus monkeys since 2002 in an effort to develop a tool for evaluating the toxicity of drug candidates.
Macrogen to Manufacture, Distribute CombiMatrix CustomArrays in Korea
CombiMatrix said this week that it has entered into a manufacturing and distribution agreement with Korean biotechnology firm Macrogen.
Specifically, Macrogen will use CombiMatrix CustomArray Synthesizers to develop and sell CustomArrays into Korea, and to offer other services based on the arrays, CombiMatrix said.
Seoul-based Macrogen's core businesses include DNA sequence analysis, biochip manufacture and research, and production of genetically engineered mice. It is also one of 11 worldwide members of Applied Biosystems' Advanced Gene Expression Service Provider Program (see BAN 2/14/2006).
CombiMatrix said that the deal underscores its strategy of establishing manufacturing and distribution relationships with regional companies to enable them to manufacture arrays onsite for their local markets.
Financial details were not disclosed.
NOTE: Due to the US Independence Day holiday,
the next issue of BioArray News will be published
on Wednesday, July 5th.